Hancock Whitney Corp Invests $235,000 in Novo Nordisk A/S (NYSE:NVO)

Hancock Whitney Corp purchased a new position in shares of Novo Nordisk A/S (NYSE:NVOGet Rating) during the 3rd quarter, HoldingsChannel.com reports. The firm purchased 2,360 shares of the company’s stock, valued at approximately $235,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Jennison Associates LLC grew its holdings in shares of Novo Nordisk A/S by 90.3% during the second quarter. Jennison Associates LLC now owns 10,517,221 shares of the company’s stock worth $1,171,934,000 after purchasing an additional 4,989,744 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Novo Nordisk A/S by 1.7% during the first quarter. Bank of America Corp DE now owns 7,440,609 shares of the company’s stock worth $826,280,000 after purchasing an additional 126,438 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Novo Nordisk A/S by 45.4% during the first quarter. BlackRock Inc. now owns 5,035,879 shares of the company’s stock worth $559,235,000 after purchasing an additional 1,571,747 shares during the last quarter. Folketrygdfondet grew its holdings in shares of Novo Nordisk A/S by 769.6% during the second quarter. Folketrygdfondet now owns 4,142,878 shares of the company’s stock worth $461,641,000 after purchasing an additional 3,666,475 shares during the last quarter. Finally, WCM Investment Management LLC lifted its stake in shares of Novo Nordisk A/S by 35.1% in the second quarter. WCM Investment Management LLC now owns 3,850,053 shares of the company’s stock worth $423,814,000 after acquiring an additional 999,342 shares during the period. 6.09% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $138.64 on Monday. The company has a quick ratio of 0.74, a current ratio of 0.92 and a debt-to-equity ratio of 0.31. Novo Nordisk A/S has a twelve month low of $91.51 and a twelve month high of $139.05. The stock’s 50 day moving average is $124.29 and its 200-day moving average is $113.07. The firm has a market capitalization of $313.74 billion, a price-to-earnings ratio of 41.14, a PEG ratio of 1.74 and a beta of 0.50.

Novo Nordisk A/S (NYSE:NVOGet Rating) last issued its earnings results on Wednesday, November 2nd. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.84 by $0.02. Novo Nordisk A/S had a return on equity of 72.57% and a net margin of 31.57%. The company had revenue of $6.17 billion for the quarter, compared to analyst estimates of $6.09 billion. Sell-side analysts forecast that Novo Nordisk A/S will post 3.37 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NVO has been the topic of a number of recent analyst reports. Cowen lifted their price objective on Novo Nordisk A/S from $130.00 to $145.00 in a research note on Monday, December 12th. Cowen lifted their price objective on Novo Nordisk A/S from $130.00 to $145.00 in a research note on Monday, December 12th. Credit Suisse Group lifted their price objective on Novo Nordisk A/S from 820.00 to 860.00 in a research note on Friday, November 4th. StockNews.com initiated coverage on Novo Nordisk A/S in a research note on Wednesday, October 12th. They issued a “strong-buy” rating on the stock. Finally, Oddo Bhf raised Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Thursday, September 29th. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $697.78.

Novo Nordisk A/S Profile

(Get Rating)

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

See Also

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVOGet Rating).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.